Lynk Pharmaceuticals Appoints Dr. Wang Weigand as Chief Medical Officer
Lynk Pharmaceuticals announced that Dr. Wang joined the company as Chief Medical Officer effectively starting from December 7, 2020.
Dr. Wang received her medical degree from Beijing Medical College, followed by a PhD in Microbiology and Immunology from Louisiana State University, Baton Rouge, Louisiana, and completed her post-doctoral training at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, USA. Dr. Wang has more than 2 decades of extensive experience and recognized achievements in global drug development and product registration. Prior to joining Lynk Pharmaceuticals, Dr. Wang served as a Sr. Vice President of Clinical Development at Seres Therapeutics, a Global Program Lead/Global Clinical Development Lead at Shire, Baxalta, and Takeda, overseeing clinical development programs across immunological and inflammatory diseases, immune-oncology, metabolic disease, vaccines, gene therapy for hemophilia, neurological disorders and recurrent CD infections.
" Lynk Pharmaceuticals is officially transitioned into a clinical stage company with three INDs granted in China and the US and one first-in-human at the end of 2020, and with several programs entering the clinical phase in 2021. I am excited to have Dr. Weigand to join the company at this critical time," said Dr. Zhao-Kui (ZK) Wan, founder & CEO of Lynk Pharmaceuticals, “Dr. Weigand has extensive clinical development experiences. We look forward to seeing an accelerated compound development under Dr.wang leadership and bringing life-saving options to the patients globally."
Dr. Wang said, “I am truly impressed by a number of highly differentiated programs at Lynk Pharmaceuticals, and I am very excited to join the company and look forward to working with Lynk’s outstanding scientific team to accelerate clinical development and bring better treatments and benefits to patients.”
About Lynk Pharmaceuticals.
Lynk Pharmaceuticals is a clinical stage company. It was founded in 2018 by senior drug discovery experts and executives from Pfizer, Merck and Johnson & Johnson. Driven by a higher purpose, Lynk Pharmaceuticals aims to be a market leader in addressing unmet medical needs through the development of innovative therapies in the fields of oncology, autoimmune and inflammation. Lynk Pharmaceuticals is positioned to become a global company with successful track of record for external collaboration, as evidenced by an out-licensing deal with a US partner (close to 200 million dollars upfront and milestone payments, plus an up to a double-digit royalty payment) and in-licensing deal with Kobe University and RIKEN of Japan on the RAS program.
Since its inception, it has won several awards and honors, including the First Place Winner in China National Innovation & Entrepreneurship Competition in 2018, Frost & Sullivan China New Economy Award – Excellence in Innovation in 2019, and Company with the Most Growth Potentials Award by the Qiantang District, Zhejiang, in 2020.